UB Paderborn / Katalog / Suche / in CDI

1 – 17 von 17

Sortiert nach

Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis

Clinical gastroenterology and hepatology, 2009-07, Vol.7 (7), p.762-769

2009

Volltextzugriff (PDF)

W1243 Impact of Once - Daily Versus Twice-Daily Mesalazine (Pentasa) On Relief of Rectal Bleeding and Stool Frequency: Results from a Multinational Randomised Controlled Trial

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-685-A-685

2009

Volltextzugriff (PDF)

T1146 Maintenance Therapy with Once-Daily 2g Mesalazine (Pentasa) Treatment Improves Remission Rates in Subjects with Ulcerative Colitis Compared to Twice Daily 1g Mesalazine: Data from a Randomised Controlled Trial

Gastroenterology (New York, N.Y. 1943), 2008, Vol.134 (4), p.A-494-A-494

2008

Volltextzugriff (PDF)

T1154 Treatment Acceptability in a Randomised Controlled Trial of Once-Daily or Twice-Daily Mesalazine (Pentasa) for the Maintenance of Remission in Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2008, Vol.134 (4), p.A-495-A-496

2008

Volltextzugriff (PDF)

Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists

Journal of medicinal chemistry, 2005-03, Vol.48 (6), p.1823-1838

2005

Volltextzugriff (PDF)

Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB1 Cannabinoid Receptor Antagonists

Journal of medicinal chemistry, 2004-01, Vol.47 (3), p.627-643

2004

Volltextzugriff (PDF)

Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity

Bioorganic & medicinal chemistry letters, 2005-11, Vol.15 (21), p.4794-4798

2005

Volltextzugriff (PDF)

Regioselective Aminomethylations of Bicyclic Phenols

Heterocycles, 2000, Vol.53 (1), p.197

2000

Volltextzugriff (PDF)

Novel 3,4-diarylpyrazolines as potent cannabinoid CB 1 receptor antagonists with lower lipophilicity

Bioorganic & medicinal chemistry letters, 2005, Vol.15 (21), p.4794-4798

2005

Volltextzugriff (PDF)

Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB 1 Cannabinoid Receptor Antagonists

Journal of medicinal chemistry, 2005-03, Vol.48 (6), p.1823-1838

2005

Volltextzugriff (PDF)

Developing and Integrating an Augmented Reality App for Teaching and Learning About Enzymes

Virtual and Augmented Reality, Simulation and Serious Games for Education, 2021, p.137-150

2021

Volltextzugriff (PDF)

Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists

Journal of medicinal chemistry, 2004-01, Vol.47 (3), p.627

2004

Volltextzugriff (PDF)

Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB 1 Cannabinoid Receptor Antagonists

Journal of medicinal chemistry, 2004-01, Vol.47 (3), p.627-643

2004

Volltextzugriff (PDF)

Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in The Netherlands

The Journal of pediatrics, 2000-06, Vol.136 (6), p.780-788, Article a106234

2000

Volltextzugriff (PDF)

ChemInform Abstract: Regioselective Aminomethylations of Bicyclic Phenols

ChemInform, 2000-04, Vol.31 (16), p.no-no

2000

Volltextzugriff (PDF)

Novel 3,4-Diarylpyrazolines as Potent Cannabinoid CB1 Receptor Antagonists with Lower Lipophilicity

ChemInform, 2006-01, Vol.37 (5), p.no-no

2006

Volltextzugriff (PDF)

Novel 3,4‐Diarylpyrazolines as Potent Cannabinoid CB 1 Receptor Antagonists with Lower Lipophilicity

ChemInform, 2006-01, Vol.37 (5)

2006

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(16)
Buchkapitel
(1)

Sprache

Englisch
(17)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis

W1243 Impact of Once - Daily Versus Twice-Daily Mesalazine (Pentasa) On Relief of Rectal Bleeding and Stool Frequency: Results from a Multinational Randomised Controlled Trial

T1146 Maintenance Therapy with Once-Daily 2g Mesalazine (Pentasa) Treatment Improves Remission Rates in Subjects with Ulcerative Colitis Compared to Twice Daily 1g Mesalazine: Data from a Randomised Controlled Trial

T1154 Treatment Acceptability in a Randomised Controlled Trial of Once-Daily or Twice-Daily Mesalazine (Pentasa) for the Maintenance of Remission in Ulcerative Colitis

Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists

Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB1 Cannabinoid Receptor Antagonists

Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity

Regioselective Aminomethylations of Bicyclic Phenols

Novel 3,4-diarylpyrazolines as potent cannabinoid CB 1 receptor antagonists with lower lipophilicity

Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB 1 Cannabinoid Receptor Antagonists

Developing and Integrating an Augmented Reality App for Teaching and Learning About Enzymes

Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists

Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB 1 Cannabinoid Receptor Antagonists

Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in The Netherlands

ChemInform Abstract: Regioselective Aminomethylations of Bicyclic Phenols

Novel 3,4-Diarylpyrazolines as Potent Cannabinoid CB1 Receptor Antagonists with Lower Lipophilicity

Novel 3,4‐Diarylpyrazolines as Potent Cannabinoid CB 1 Receptor Antagonists with Lower Lipophilicity

Suchergebnisse filtern